Autres langues Precigen, Inc.

Actions

PGEN

US74017N1054

Temps réel estimé Cboe BZX Autres places de cotation 21:17:09 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,505 ^USD	-0,33%		-2,27%	+12,31%

04/06	Transcript : Precigen, Inc. - Special Call
03/06	PRECIGEN, INC. : Stifel Nicolaus optimiste sur le dossier	ZM

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free	03/06
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response	03/06
Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M	14/05
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting	25/04
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	24/04
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th	28/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Precigen Shares Fall After Downgrade From JPMorgan	22/03
Precigen Reports Full Year 2023 Financial Results and Business Updates	20/03
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
North American Morning Briefing : Stock Futures -2-	19/03
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	12/03
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th	05/03
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe	16/01
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16/01
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16/01
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference	09/01
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference	18/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Precigen, Inc.

Actions

PGEN

US74017N1054

Autres langues

Filtres